Hyponatraemia and congestive heart failure refractory to diuretic treatment. Utility of tolvaptan
Pose A (1), Almenar L (2), Manzano L (3), Gavira JJ (4), López Granados A (5), Delgado J (6), Aramburu O (7), Arévalo JC (8), Méndez M (9), Comín J (10), Manito N (11).
Heart failure (HF) is currently one of the most significant healthcare problems in Spain and has a continuously increasing prevalence. Advances in our understanding of the various biological responses that promote cardiac remodelling and pulmonary venous congestion constitute the basis of current treatment.
This article, prepared by members of the HF groups of the Spanish Society of Cardiology and the Spanish Society of Internal Medicine, discusses the current therapeutic strategies for patients with congestion refractory to diuretic treatment.
The article includes our clinical experience with the use of tolvaptan as an additional treatment for congestion associated with hyponatraemia. To this end, we propose an algorithm for the use of tolvaptan in patients with congestive HF, natraemia <130mEq/l and poor response to conventional diuretic treatment.
CITATION Rev Clin Esp. 2017 Mar 31. pii: S0014-2565(17)30076-0. doi: 10.1016/j.rce.2017.02.013